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CObjective: In 2004, Willke and colleagues reviewed the efficacy
endpoints reported in the labels of new drugs approved in the United
States from 1997 through 2002 to evaluate the use of patient-re-
ported outcome (PRO) endpoints. Of the labels reviewed, 30% in-
cluded PROs. Our study aimed to build on this work by describing the
current state of PRO label claims granted for new molecular entities
(and biologic license applications since February 2006 after the re-
lease of the US Food and Drug Administration (FDA) draft PRO
guidance. Methods: All new molecular entities and biologic license
pplications approved by the FDA from January 2006 through Decem-
er 2010 were identified by using the Web page of the FDA Drug Ap-
roval Reports. For all identified products, drug approval packages and
pproved product labels were reviewed to identify PRO endpoint status O
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oi:10.1016/j.jval.2011.11.032nd to determine the number and type of PRO claims. Results: Of the
16 products identified, 28 (24%) were granted PRO claims; 24 (86%)
ere for symptoms, and, of these, 9 (38%) claims were pain related.
f the 28 products with PRO claims, a PRO was a primary endpoint
or 20 (71%), all symptom related. Conclusions: The FDA continues to
pprove PRO claims, with 24% of new molecular entities and biologic
icense applications being granted. Successful PRO label claims over
he past 5 years have generally supported treatment benefit for symp-
oms specified as primary endpoints.
eywords: drug labeling, patient-reported outcomes.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The content of package inserts from the US Food andDrug Admin-
istration (FDA) is vital to the commercial success of a medicinal
product. These package inserts, also called product labels, consti-
tute the formal, government-approved definition of a drug’s ben-
efits and risks. Package inserts arewritten by (and are the property
of) the manufacturer but require FDA approval; they define the
boundaries of the legal promotion of a product’s properties [1].
Patient-reported outcome (PRO) is an umbrella term that com-
prises a range of potential measurement endpoints, but it is used
specifically to describe outcomes collected directly from the patient,
without interpretation by clinicians or others [2,3]. PRO use is partic-
ularly common for products developed to treat chronic, disabling
conditionswhere the intention is not necessarily to cure but to ame-
liorate symptoms, facilitate functioning, or improve quality of life.
PROs are the primary endpoints in clinical trials evaluating drug
products for disease areas such as irritable bowel syndrome, mi-
graine, and pain. PROs provide key supportive data in many other
disease areas, such as insomnia, asthma, and psychiatric disorders.
In oncology, PROs are commonly used to assess both treatment ben-
efits and toxicity to fully evaluate the impact of treatment on health-
related quality of life (HRQOL). PROs can also be used in clinical trials
to assess treatment satisfaction, compliance, and caregiver burden.
* Address correspondence to: Ari Gnanasakthy, Novartis Pharmac
E-mail: ari.gnanasakthy@novartis.com.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.Increase in the use of formal questionnaires in clinical trials [4],
advances in methodological rigor in measurement science during
the 1980s and the 1990s [5], and the need to standardize the ter-
minology [2] led to the guidance on PROs from the FDA, especially
ecause it is related to drug labeling and promotion.
For drugmanufacturers seeking PRO claims, the FDA’s release of
draft guidance in 2006 [6] and a final guidance in 2009 [7] (Guidance
or Industry. Patient Reported Outcomes: Use in Medical Product Develop-
ent to Support Labeling Claims [PROguidance])was a landmark event.
he PRO guidance describes the use of PROs to support potential
laims in product labeling. Based on this PRO guidance document,
ROs may be used to support treatment benefit claims in FDA-ap-
roved product labeling. The claimsmust be supported by appropri-
tely designed investigations using PROs that have been demon-
trated to measure the concept underlying the claim [3].
International societies have held workshops to debate the im-
act of the FDA PRO guidance, and journals have hosted special
ssues devoted entirely to this topic [8]. It is generally agreed that
he PRO guidance has set a high standard for developing and im-
lementing PRO measures in clinical trials for new drug products
nd has also provided a blueprint for sponsors who wish to obtain
RO label claims for their products [9].
A review of PRO labels granted from 1997 through 2002 [10]
howed that PROevidencewas cited in theClinical Studies section of
als Corporation, One Health Plaza, East Hanover, NJ 07936, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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productswere approved on the basis of PROs alone. Our study aimed
to build on the work by Willke et al. [10] by describing the current
state of PRO label claims granted for new molecular entities (NMEs)
and biologic license applications (BLAs) from 2006 through 2010.
The purpose of this study was to compile and review the PRO
label claims granted over the 5 years since the release of the draft
PRO guidance (2006–2010) [6]. Moreover, we were interested in
understanding the types of claims granted based on PROs. We
hypothesized that PRO claims would be more likely for first-order
impact assessments such as symptoms, rather than for more
complex concepts such as HRQOL.
Methods
Products reviewed in this analysis includednewdrugs approved in
the United States from January 2006 through December 2010. The
Web page of the FDA Drug Approval Reports was used to deter-
mine the number of products approved in the time period of in-
terest. The report options selected were original new drug approv-
als (NDAs) and BLAs bymonth;monthswere selected sequentially
beginning with January 2006 and ending in December 2010. The
reports include a specification of the Center for Drug Evaluation
Research NDA chemical classification. Our review included prod-
ucts classified by the Center for Drug Evaluation Research as NMEs
or BLAs. Therefore, we excluded products containing substances
previously marketed with a different brand name or a set of indi-
cations, as a different dosage formor strength, or as a combination
product of previously marketed entities.
Once products were identified, drug approval packages (DAPs)
and approved product labels were reviewed. As available, informa-
tion was retrieved from the Medical Review, Summary Review,
Cross-Discipline Team Leader Review, and other review sections
fromtheDAP, aswell as the IndicationandClinical Studies sectionof
theapprovedproduct label. TheDAPswere locatedon theFDA’sWeb
site Drugs@FDA (www.accessdata.fda.gov). In most cases, the prod-
uct labelwasalso foundon this FDAWebsiteunder approvalhistory.
In theevent theapproved labelwasunavailable for the specified time
frame, the current label was evaluated. As available, the following
information was collected for each US drug product identified:
● Brand name
● Generic name
● Date of approval
● Applicant
● Label indication
● PRO claim language
● PRO measures named in label
● Reviewing division
● Medical review available (yes/no)
● Indication in DAP of Study Endpoints and Label Development
(SEALD) review (yes/no) and comments
● PRO measures mentioned in the label and DAP, and endpoint
status (primary, secondary, tertiary/exploratory)
● PRO results reported as statistically significant (yes/no)
PRO claim language from the Indication and Clinical Studies
sections of the label was reviewed and characterized as symptoms
(yes/no), functioning (yes/no), HRQOL (yes/no), patient global rat-
ing (PGR) (yes/no), or other (yes/no). A single rater applied standard
definitions to the review of the labels for characterization.
Symptoms were defined as any subjective evidence of a dis-
ease, health condition, or treatment-related effect that can be no-
ticed and known only by the patient. Functioning claims related to
restriction or lack of ability to perform an activity(ies) in the man-
ner or within the range considered normal. HRQOL claims were
defined as those referencing a multidomain concept representing Pthe patient’s general perception of the effect of illness and treat-
ment on physical, psychological, and social aspects of life. A PGR
was defined as any assessment or evaluation of the patient’s dis-
ease or condition identified as “global.” These classifications are in
line with the definitions provided in the final PRO guidance and
the work previously reported by Caron et al. [11]. A product label
may contain more than one PRO claim.
Statistical analysis consisted of frequencies and cross tabula-
tions ofmeasured characteristics. Calculationswere performed by
using Microsoft Excel 2007.
Results
A total of 156 new drugs were approved during this period. DAPs
were located and reviewed for all 156 products. The DAPs for all
products contained medical reviews. Some DAPs also included
summary reviews or cross team leader reviews or both. Product
labels were located for all the products. Of the 156 approvals, 33
were granted tentative approvals and full approval will not be
granted until after patent exclusivity expires. Because these were
for generic products, we excluded them from our analysis. Some
drugs approved during this period were subsequently removed
from the market but were nonetheless included in this analysis.
Denosumab, although registered as both Prolia and Xgeva, was
considered a single new drug with the same clinical studies for
registration and a single BLA supporting both. Similarly, Natazia
was considered a single new drug because the same clinical stud-
ies were used in the registration files and a single NDA supported
it. Sabril was considered a single new drug despite two unique
NDA numbers supporting the different formulations. Finally, there
were four new products approved with no data available on the
FDA’s Web site, including a label, at the time of our data extraction
and analysis and so these products were excluded from this review.
Therefore, a total of 116 products were included in this review.
Of the 116 products reviewed, the largest number (n  16) was
eviewed by the Drug Oncology division, followed by Neurology
roducts (n 11), Cardiovascular and Renal Products (n 10), and
Anesthesia, Analgesia, and Rheumatology Products (n  10) divi-
sions (Table 1). PRO claims appeared in 28 product labels (24% of
the 116 products reviewed) across 11 reviewing divisions. The in-
dications for all 28 products with PRO claims in the label are avail-
able in Appendix A in Supplemental Materials found at doi:
10.1016/j.jval.2011.11.032). Among the 28 products with PRO claims
in the label, Neurology Products (n 7; 25.0%) and Anesthesia, Anal-
gesia, and Rheumatology Products (n  6; 21.4%) divisions granted
themost PRO label claims. Approximately two-thirds of the products
reviewed by the Neurology Products; Anesthesia, Analgesia, and
Rheumatology Products; and Pulmonary and Allergy Products re-
viewing divisions received PRO claims in the label. The following
reviewing divisions did not grant any PRO label claims: Drug Oncol-
ogy; Biologic Oncology; Antiviral, Dermatology, and Dental Products;
and Special Pathogen and Transplant Products.
The 28 products received a total of 38 PRO label claims (Table 2).
The majority of the products (n  20; 71%) received one PRO label
claim. The products with one PRO label claim were characterized
as follows: symptoms (n  16), functioning (n  1), HRQOL (n  1),
nd other (n 2). Of the eight products that receivedmultiple PRO
abel claims, six received two PRO label claims and two products
eceived three PRO label claims (symptoms, functioning, and PGR).
f the 28 products with PRO label claims in the Clinical Studies
ection of the label, 14 (50%) also contained PRO claims within
heir indication statements. Only one of the claims reviewed ap-
eared in themedication guide. There were no PRO claims related
o decrements in health.
Most PRO label claims granted were for symptoms (85.7%) and
unctioning (25%) (Table 2). A few products (n  3; 10.7%) received
RO label claims on the basis of PGRs (e.g., seizure severity and
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claims classified as other: these were patient satisfaction with
treatment (Asclera) and distress associated with belly appearance
(Egrifta). Pain continues to be a prominent symptomamong the PRO
label claimsgranted, rankinghighest (n7) among the16 symptoms
label claims followed by allergy-related symptoms (n  5). The con-
cepts of pain and reduced pain appear straightforward, and as such,
little was discussed in the DAPs regarding the measurement of pain
itself. Pain assessments via visual analogue scales and numeric rat-
Table 1 – Number of products approved and number of PRO
Reviewing division Products
Anesthesia, Analgesia and Rheumatology
Products
Chantix,* Arcalyst,* Nuc
Uloric, Simponi,* Ilari
Antimicrobial Products Durezol*
Anti-infective and Ophthalmology Products Lucentis, Altabax, Dorib
Bepreve,* Lastacaft,* T
Antiviral Products Prezista, Tyzeka, Selzen
PegIntron/Rebetol Com
hydrocortisone, Zidov
Biologic Oncology Products Vectibix, Arzerra
Cardiovascular and Renal Products Tekturna, Letairis,* Byst
Tyvaso, Effient, Multa
Dermatology and Dental Products Veregen, Ulesfia, Stelara
Drug Oncology Products Dacogen, Sprycel, Zolin
Ixempra Kit, Tasigna,
Mozobil, Afinitor, Folo
Jevtana, Halaven
Gastroenterology Products Myozyme, Elaprase, Cim
Vpriv, Carbaglu, Lum
Medical Imaging and Hematology Products Soliris,* Ammonia N 13,
Eovist, Nplate, AdreV
Metabolism and Endocrinology Products Januvia, Somatuline Dep
Livalo, Victoza, Egrifta
Neurology Products Azilect,* Neupro, Xenaz
Dysport,* Extavia, Sab
Ampyra,* Xeomin,* Gi
Nonprescription Clinical Evaluation
Products
Anthelios SX, Cetirizine
Cetirizine Hydrochlor
Psychiatry Products Invega , Vyvanse,* Pristi
Sustenna, Saphris, La
Pulmonary and Allergy Products Omnaris,* Kalbitor,* Kry
Reproductive and Urologic Products Toviaz,* Rapaflo,* Nataz
Special Pathogen and Transplant Products Eraxis, Noxafil, Pylera, C
Total
PRO, patient-reported outcome.
* Products with PRO claims in the label.
Table 2 – Types of claims granted.
Type of claim All products
with PRO
claims
(N  28)
Pain products
excluded
(N  21)
n % n %
Symptoms 24 85.7 14 66.7
Functioning 7 25.0 3 14.3
HRQOL 2 7.1 2 9.5
PGR 3 10.7 1 4.8
Other 2 7.1 2 9.5HRQOL, health-related quality of life; PGR, patient global rating.ing scales are common, with little (if any) discussion in the DAPs
surrounding the question stem or anchors used.
More than 30 different PRO measures were used to support the
PRO claims received (Table 3). The bulk of the measures were de-
signed tomeasure a single concept such as pain or seizure rates (n
8) or diary assessments (n 6). Another large proportion of themea-
sures appears to be expected by the reviewing divisions given their
familiarity with themeasures (n 9) (e.g., Health Assessment Ques-
tionnaire, Short Form 36 Health Survey, and International Prostate
Symptom Score). We noted several hybrid measures that combined
both clinician-reported outcomes and PROs into a single measure-
ment tool (e.g., Toronto Western Spasmodic Torticollis Rating Scale
and Activities of Daily Living andMotor subscales of the Unified Par-
kinson’s Disease Rating Scale). Although these hybrid measures are
not solely patient reported, they contain PROs that are critical to as-
sessing efficacy in the given indications.
The extent of information identified in the label regarding the
specific PRO measures used to support the label claim was vari-
able. Some labels included very little information regarding the
PRO assessment. For example, the assessment of ocular itching in
the Lastacaft label is not described at all (“more effective than its
vehicle in preventing ocular itching in patients with allergic con-
junctivitis induced by ocular allergen challenge”). Other labels in-
cluded more specific information regarding the PRO assessment.
For instance, the Egrifta label has a subsection on PRO within the
Clinical Studies section. The description of patient-rated degree of
ims granted by reviewing divisions.
ewed Number of
products
approved
Number of products
that include a PRO
claim
* Lusedra, Savella,*
emra,* Xiaflex
10 6
1 1
esivance, Vibativ,
o
8 2
entress, Intelence,
ack, acyclovir,
e
8 0
2 0
leviprex, Samsca,
clera,* Pradaxa
10 2
3 0
kerb, Torisel,
nda, Firmagon,
Votrient, Istodax,
16 0
Relistor, Entereg, 8 1
era, Lexiscan,
romacta, Ablavar
9 1
uvan, Onglyza, 7 1
impat,* Banzel,*
0-mg tablet,*
11 7
ochloride Allergy,*
ives Relief*
3 2
apt, Invega 7 1
a 3 2
a, Prolia 5 2
m, Zortress 5 0
116 28cla
revi
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s, Act
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oartedistress in the Egrifta label includes the following:
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pearance on a 9-point rating scale that was then transformed to a
score from0 [extremely upsetting anddistressing] to 100 [extremely
encouraging]. A score of 50 indicated neutral [no feeling eitherway].
A positive change from baseline score indicated improvement, i.e.,
less distress.
In addition, certain therapeutic areas included extensive informa-
tion regarding thePROassessment,where itwas theprimaryefficacy
endpoint (e.g., Omnaris label for seasonal allergic rhinitis).
A PRO was the primary endpoint for 20 of the 28 (71%) products
Table 3 – Measures used to support PRO label claims.
Type of claim/product M
Symptoms
Azilect Diary: “On/off” periods
Chantix Brief Questionnaire of Smoking
Omnaris Diary: Nasal symptoms (runny
Vyvanse Conners’ Parent Rating Scale
Soliris Functional Assessment of Chro
Arcalyst Diary: Signs and symptoms of
fever/chills, eye redness/pai
Cimzia Crohn’s Disease Activity Index
Durezol Visual analogue scale—eye pai
Toviaz Diary: Urge urinary incontinen
Rapaflo International Prostate Symptom
Vimpat Seizure frequency
Banzel Seizure severity from the Paren
Nucynta Pain numeric rating scale
Savella Pain visual analogue scale
Dysport TWSTRS†
Simponi Health Assessment Questionn
Cetirizine hydrochloride-allergy Diary: Symptoms include snee
the eyes
Cetirizine hydrochloride-hives Diary: Severity and duration of
Sabril Complex partial seizures—seiz
Bepreve Ocular itching
Kalbitor Mean Symptom Complex Seve
Actemra Pain visual analogue scale
Xeomin TWSTRS subscales†
Lastacaft Ocular itching
Function
Azilect Activities of Daily Living and M
Savella Physical function (Short Form
Dysport TWSTRS subscales†
Simponi RA and PSA: Health Assessmen
Spondylitis Functional Index
Ampyra 12-Item Multiple Sclerosis Wal
Actemra Health Assessment Questionn
Xeomin TWSTRS subscales†
HRQOL
Soliris European Organisation for the
30 Items*
Letairis Short Form 36 Health Survey
PGR
Banzel Seizure severity from the Paren
Savella Patient global assessment of ch
Simponi Patient global assessment of ch
Other
Asclera Patient satisfaction (verbal rati
Egrifta Distress associated with belly a
HRQOL, health-related quality of life; PGR, patient global rating; PRO
collis Rating Scale.
* Not mentioned in label.
† Hybrid clinician-reported and patient-reported measure.with PRO label claims (Table 4). All 20 primary endpoints were basedon symptoms. PRO label claims were granted for nonprimary
endpoints for 8 of the 28 (29%) products. The four products for which
a PROwas not a primary endpoint and where a symptom claimwas
not granted were those granted PRO claims for distress (Egrifta), sat-
isfaction (Asclera), HRQOL (Letairis), and functioning (Ampyra).
Three products received PRO claims on the basis of PGRs.
These included a measure of seizure severity from the parent/
guardian global evaluation of the patient’s condition (Banzel), a
patient’s global assessment of disease activity (Simponi), and a
patient global impression of change (Savella). The Banzel label
ure description supporting claims
s and Minnesota Nicotine Withdrawal Scale
, nasal itching, sneezing, and nasal congestion)
llness Therapy—Fatigue*
yrin-associated periodic syndrome: joint pain, rash, feeling of
fatigue
comfort*
isodes and number of micturitions (frequency)*
re
ardian Global Evaluation of the patient’s condition
Disability Index and Bath Ankylosing Spondylitis Functional Index†
rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of
s and pruritus
equency
nd Treatment Outcome Score
subscale of the Unified Parkinson’s Disease Rating Scale†
alth Survey physical component summary)
estionnaire—Disability Index and AnkSpon: Bath Ankylosing
Scale
rch and Treatment of Cancer—Quality of Life Questionnaire Core
ardian Global Evaluation of the patient’s condition
ale)
rance
ent-reported outcome; TWSTRS, Toronto Western Spasmodic Torti-eas
Urge
nose
nic I
cryop
n, and
†
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ce ep
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t/Gu
aire—
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hive
ure fr
rity a
otor
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, patispecifies the PGR as one of the three primary efficacy variables:
441V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 3 7 – 4 4 2. . . seizure severity from the Parent/Guardian Global Evaluation of
the patient’s condition. This was a 7-point assessment performed
at the end of the Double-blind Phase. A score of 3 indicated that
the patient’s seizure severity was very much improved, a score of 0
that the seizure severity was unchanged, and a score of 3 that the
seizure severity was very much worse.
Results of the three primary endpoints, including the PGR, are
presented within a table within the label.
Within the DAPs, SEALD was mentioned as providing a review
for the following four products: Chantix, Soliris, Cimzia, and Eg-
rifta. In the case of Chantix, SEALD personnel were named and
their specific comments were directly available for review as part
of the DAP, whereas for Soliris and Egrifta, a summary of the
SEALD review and comments was referenced in the context of the
medical team’s review but specific comments from identified
SEALD reviewerswere not available. For Cimzia, only the names of
FDA personnel involved with the product review revealed SEALD
team involvement. There was no evidence in the other DAPs as to
whether SEALD provided additional consultation to the reviewing
division.
The extent of publicly available information regarding the la-
beling discussion itself is limited because proposed labeling lan-
guage is considered proprietary. Nevertheless, the Egrifta DAP re-
veals that in response to the comments and recommendations
made by the SEALD consult, the clinical and statistical team de-
cided to include in the label only the results of the belly appear-
ance distress. It was noted by the Reviewing Division that
froma clinical perspective Belly AppearanceDistress is an endpoint
of higher significance as it does not measure the self-reported per-
ception about changes in the size of the abdomen but rather the
emotional impact and distress for the patient, an important proxy
for QOL in HIV-patients with lipodystrophy. As recommended by
the SEALD consult, the term XXX will no longer be included in Eg-
rifta label description of this PRO since, although developed with
advice, it no longer meets the new standard set by the December
2009 FDA PRO guidance.
Discussion
This reviewprovides a compilation and categorization of PRO label
claims granted since the release of the draft PRO guidance in 2006
[6]. Although a similar review of PRO labels for the 3 years imme-
diately before the release of the draft PRO guidance is not available
(2003–2005), this review provides an opportunity to compare the
current state of PRO label claims over the 5-year period since the
release of the draft PRO guidance (2006–2010) with that reported
by Willke et al. between 1997 and 2002 [10].
Despite the hope that after the release of the PRO guidance the
proportion of NMEs and BLAs with PRO label claims would in-
crease given the established guidelines [12], our results indicate
that this proportion has decreased slightly from 30% reported by
Willke et al. to 24%. Our findings, based on NMEs and BLAs, are
similar to the 21.5% reported by Marquis et al. [13], which was
Table 4 – PRO primary endpoint and symptom claims.
PRO primary
endpoint
Total number
of products
Yes
(n  20)
No
(n  8)
Symptoms claim: Yes 20 4 24
Symptoms claim: No 0 4 4
Total 20 8 28
PRO, patient-reported outcome.based on all products over the same time period as of our review.The guidance from the FDA has provided the pharmaceutical
industrywithmuchmore information regarding regulatory expec-
tations than ever previously available. Our review, however, sug-
gests that there is disparity across reviewing divisions in terms of
the proportion of PRO label claims granted. Although several re-
viewing divisions have granted PRO label claims, others have yet
to grant any since the release of the draft PRO guidance in 2006.
For example, although the FDA guidance for industry on oncol-
ogy clinical trial design cites symptoms as a direct efficacy
endpoint that can be used to support regulatory approval [14,15],
only 4 of the 57 approvals from 1990 through 2002 were based on
decrease in tumor-specific symptoms [16]. Gondek et al. [14] re-
ported findings of an analysis of PRO claims among product labels
for oncology. From a pool of 70 new or revised product labels (from
January 2002 through September 30, 2006), therewere six labels for
a new product or a new indication that contained PRO assess-
ments based on symptoms (n  5) and functions (n  1) [14]. Yet
there have not been any PRO label claims for oncology products
since the release of the draft PRO guidance.
Occurrences of symptoms are the most commonly reported
PRO label claims granted. This finding, based on the analysis of
NMEs and BLAs since the release of the draft PRO guidance in 2006
[6], is similar to the findings from previous analyses of all PRO
labels in the United States [17] and Europe [11]. The dominance of
symptom-based PRO claims may be twofold. First, symptoms are
typically the first-order impact of many diseases and treatments.
Second, most symptom occurrences that can be quantified by fre-
quency, severity, and duration are easy to measure on simple
scales and with patient diaries in clinical trials conducted in mul-
tiple regions.
Our analyses also show that many PRO measures used for the
purpose of label claims can be considered to be well established in
the literature on the basis of the frequency of use in clinical trials
and available information on their development and psychomet-
ricmeasurement properties (e.g., Short Form36Health Survey and
Health Assessment Questionnaire).
Patient diaries continue to be used prolifically in capturing PRO
data. Diaries capture simple items, such as seizure frequency, sever-
ity and duration of pruritus, and the on/off cycle of Parkinson’s
symptoms,and thus tend to result in simplePRO labelingclaims (e.g.,
reduction in 28-day seizure frequency and prevention of itching).
PRO label claims for nonprimary endpoints are uncommon
from the FDA. There are three likely reasons for this.
1. Primary and nonprimary endpoints tend to measure the same
domain. Furthermore, such claims, overemphasizing the effi-
cacy of products, are often the target for warning letters from
the Division of Drug Marketing, Advertising, and Communica-
tions [18].
2. Sponsors are unlikely to commit resources for nonprimary
endpoints during the early stages of product development,
which can be substantial for developing new PRO measures
aimed at multinational studies, when the likelihood of changes
to the target product profile and the rate of attrition are still
high.
3. Sponsors may be reluctant to support the logistical complexi-
ties related to nonprimary PRO endpoints during the execution
of a multinational study. For example, protocol amendments,
such as changes to inclusion and exclusion criteria for patient
characteristics while the study is ongoing, will preserve the in-
tegrity of the primary endpoint butmay affect the validity of the
nonprimary PRO endpoint. In addition, slow patient recruit-
ment in studiesmay necessitate the need to close study centers
in some countries and open new centers in other countries.
Sponsors are unlikely to wait for the availability of new trans-
lations of PRO measures and take time to implement data col-
D
u
a
t
t
b
p
c
l
b
v
r
l
h
[
[
[
[
[
[
[
[
[
442 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 3 7 – 4 4 2lection logistics, which may delay the study by months, to sup-
port nonprimary PRO endpoints.
This review was based on information publicly available in
APs on FDA’s Web site. Additional material, of which we were
naware or that was unavailable to us, may have been considered
s part of the FDA review. Furthermore, SEALD acts on a consul-
ancy basis and therefore not all reviews received (or required)
heir input regarding the PROs.
Conclusions
The percentage of NMEs and BLAs with PRO label claims has de-
creased from 30% [10] reported between 1997 and 2002 to 24%
etween 2006 and 2010. PRO label claims are granted mostly for
rimary endpoints that are also symptoms. The majority of ac-
epted claims are supported by simple scales, such as a visual ana-
ogue scale, a numeric rating scale, or symptom diaries, or on the
asis of measures that have been traditionally accepted by the re-
iewing divisions. Examination of future sponsor submissions and
egulatory feedback for studies planned and executed since the re-
ease of the final PRO guidance may provide additional insight into
ow to increase success in obtaining PRO-based label claims.
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